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Abstract
Multiplex families with a high prevalence of a psychiatric disorder are often examined to identify rare genetic variants with
large effect sizes. In the present study, we analysed whether the risk for bipolar disorder (BD) in BD multiplex families is
influenced by common genetic variants. Furthermore, we investigated whether this risk is conferred mainly by BD-specific
risk variants or by variants also associated with the susceptibility to schizophrenia or major depression. In total, 395
individuals from 33 Andalusian BD multiplex families (166 BD, 78 major depressive disorder, 151 unaffected) as well as
438 subjects from an independent, BD case/control cohort (161 unrelated BD, 277 unrelated controls) were analysed.
Polygenic risk scores (PRS) for BD, schizophrenia (SCZ), and major depression were calculated and compared between the
cohorts. Both the familial BD cases and unaffected family members had higher PRS for all three psychiatric disorders than
the independent controls, with BD and SCZ being significant after correction for multiple testing, suggesting a high baseline
risk for several psychiatric disorders in the families. Moreover, familial BD cases showed significantly higher BD PRS than
unaffected family members and unrelated BD cases. A plausible hypothesis is that, in multiplex families with a general
increase in risk for psychiatric disease, BD development is attributable to a high burden of common variants that confer a
specific risk for BD. The present analyses demonstrated that common genetic risk variants for psychiatric disorders are likely
to contribute to the high incidence of affective psychiatric disorders in the multiplex families. However, the PRS explained
only part of the observed phenotypic variance, and rare variants might have also contributed to disease development.
Introduction
Bipolar disorder (BD), characterised by alternating episodes
of mania and depression, has a lifetime prevalence of ~1%
and is a substantial contributor to disability throughout the
world [1]. Nevertheless, reliable data concerning the
aetiology of BD remain scarce. The heritability of BD is
estimated to be above 70% [2–4], thus demonstrating an
important genetic component in the development of the
disorder. Genome-wide association studies (GWAS) in
case/control samples have reported that single-nucleotide
polymorphisms (SNP) with minor allele frequencies (MAF)
of ≥ 1% explain a substantial proportion of the genetic risk
for BD [5–12]: the heritability explained by such common
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variants (i.e., the SNP heritability) is estimated to be
0.17–0.23 on a liability scale [12]. Common variants also
make a substantial contribution to the development of
schizophrenia (SCZ) and major depressive disorder (MDD)
[13, 14]. These three psychiatric disorders have a shared
genetic component, whereby relatives of patients with BD
have, in addition to BD, an increased risk for MDD and
SCZ [15]. In fact, GWAS have shown that many genetic
risk variants are associated with all three disorders [16–21].
Besides common variants with small individual effects,
rare variants with larger effects may also contribute to BD
development [22, 23]. In theory, such rare variants should
be enriched in families with a high prevalence of illness,
termed multiplex families, in comparison to unrelated BD
cases. However, it remains unclear whether and to what
extent disease incidence in multiplex families is caused by
rare variants, a high load of common variants, or a com-
bination of both.
To elucidate the molecular genetic causes of BD, we
established the Andalusian Bipolar Family (ABiF) study in
1997, which recruited BD multiplex families [24–26]. In the
present analyses, we first investigated whether common
genetic variants make a significant contribution to the occur-
rence of BD in ABiF families. Next, we examined whether BD
development was attributable to (a) BD-specific risk variants,
(b) variants conferring risk to all three disorders BD, MDD,
and SCZ, or, (c) a combination of both. To this end, polygenic
risk scores (PRS) based on GWAS of BD, MDD, and SCZ
were calculated for and compared between ABiF family
members and unrelated BD cases and unrelated controls from
the same population. Because of the strong genetic correlation
between BD, SCZ, and MDD, standard PRS for BD cannot
distinguish between BD-specific risks and factors shared
between these disorders. To differentiate between genetic risk
shared across and specific to any of the three disorders, we
calculated PRS of disorder-specific risk variants using genome-
wide inferred statistics (GWIS) and PRS of shared risk var-
iants. To evaluate the possibility that population or technical
differences between cohorts biased the results on psychiatric
PRS, PRS for late-onset Alzheimer’s disease (LOAD) and
simulated PRS were analysed as negative controls. Assuming a
polygenic model with a contribution of common risk variants,
we expected increased psychiatric PRS in the ABiF family
members compared to unrelated samples and increased psy-
chiatric PRS in patients compared to controls.
Materials and methods
Sample description
The ABiF study recruited BD multiplex families in Anda-
lusia, Spain [24–26]. The present analyses included 395
members of 33 ABiF families. Diagnoses were assigned by
two trained clinicians according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM)-IV criteria
using the best estimate approach [24]. Diagnoses com-
prised (Table 1 and Supplementary Table S1): BD, n= 166
(families (FAM)BD; BD type I (BD-I): n= 115; BD type II
(BD-II): n= 41; not otherwise specified (NOS) BD: n=
10); MDD, n= 78 MDD (FAMMDD); no history of an
affective disorder, n= 151 (FAMunaffected). Six unaffected
individuals with a history of substance abuse were excluded
from the analyses. Forty-four subjects married into the
families and had no parent in the ABiF cohort (36 unaf-
fected; 8 MDD). Furthermore, an independent, previously
reported Spanish BD case/control (CC) sample was ana-
lysed. Here, BD cases (CCBD) were recruited from con-
secutive clinical admissions and BD was diagnosed, as in
the ABiF families, using DSM-IV [9]; unrelated control
individuals (CCcontrols) were recruited in the framework of
the longitudinal European Community Respiratory Health
Survey (ECRHS) study. Blood for genotyping was acquired
at the ECRHS2 assessment in 2000–2001. After quality
control (QC), the combined data set of both cohorts com-
prises data from 384 FAM (163 FAMBD, 73 FAMMDD, 142
FAMunaffected, and 6 FAMunaffected with a history of substance
abuse) and 438 CC subjects (161 unrelated BD cases; BD-I:
n= 156; BD-II: n= 5) and 277 unrelated controls. Of the
161 CCBD cases, 59 (36.6%) reported a family history of
BD. However, in contrast to the data collection in the ABiF
families, this information relied only on the self-report by
the respective CCBD patient, and was not validated via an
interview of further family members. BD diagnoses were
not available for the unrelated controls, but the self-reported
prevalence of current depression in this cohort was 3.3% at
the time of genotyping and the self-reported prevalence of
lifetime depression was 14.4% at the follow-up 10 years
after genotyping, indicating that the cohort is fairly repre-
sentative of a typical population in regard to the prevalence
of depression [27].
Note that, while all subjects passed QC in the family-
only sample, 11 family members were excluded
during QC of the joint sample because they showed sig-
nificant differences in autosomal heterozygosity from
the mean. Reported numbers of subjects thus differ
slightly for different comparisons. The joint data set
contained 35 unaffected, married-in family members
who were excluded from analyses using the combined
sample (unless specified otherwise). A detailed descrip-
tion of QC procedures is provided in the Supplementary
Methods.
The study was approved by the respective local ethics
committees (Comités de ética de la investigación provincial
de Cádiz, Córdoba, Granada, Jaén and Málaga), and all
participants provided written informed consent. For five
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adolescents (age 15–17 years), written informed consent
was also obtained from the parents.
Genotyping and imputation
Genome-wide genotyping of the FAM sample was carried
out using the Illumina Infinium PsychArray BeadChip
(PsychChip). QC and population substructure analyses
were performed in PLINK v1.9 [28], as described in the
Supplementary Methods. Genotyping and basic QC of the
CC sample were conducted previously and are described
elsewhere [9]. The study used two genotype data sets:
Analyses of family members by themselves used variants
genotyped on the PsychChip. For analyses on the com-
bined FAM+ CC sample, the genotype data of the CC
data set were, for the variants genotyped in both samples,
merged with the genotype data of the FAM sample. Both
genotype data sets (family-only and combined) were
imputed independently to the 1000 Genomes phase 3
reference panel using SHAPEIT and IMPUTE2 [29–31].
After imputation and post-imputation QC, the combined
data set of both cohorts contained 6,862,461 variants with
an INFO metric of ≥ 0.8 and a MAF of ≥ 1%. The imputed
FAM data set without the CC subjects contained
8,628,089 variants.
Calculation of polygenic risk scores
PRS were calculated in R v3.3 [32] using imputed genetic
data. For each PRS, the effect sizes of variants below a
selected p-value threshold, both obtained from large GWAS
(training data), were multiplied by the imputed SNP dosage
in the test data and then summed to produce a single PRS
per threshold. Test statistics and alleles in the GWAS
training data were flipped so that effect sizes were always
positive. Thus, the PRS represent cumulative, additive risk.
PRS were scaled to represent the relative risk load (mini-
mum possible cumulative risk load= 0, maximum= 1). For
each disorder, ten PRS based on different GWAS p-value
thresholds (<5 × 10−8, <1 × 10−7, <1 × 10−6, <1 × 10−5,
<1 × 10−4, <0.001, <0.01, <0.05, <0.1, <0.2) were calcu-
lated. The number of SNPs used for each PRS is shown in
Table 1 Characteristics of 389 individuals from the 33 ABiF families, the 161 unrelated bipolar cases (CCBD), and the 277 unrelated controls
(CCcontrols)
FAMBD
(n= 166)
FAMMDD
(n= 78)
FAMunaffected
(n= 145)
CCBD
(n= 161)
CCcontrols
(n= 277)
Median age at interview (MAD) 40.5 (12.5) 44.5 (11.5) 44 (15)d 44 (11)d 43 (6)b,c
Missing= 3
Median age at onset (MAD) 20 (5)c
Missing= 3
26 (8)a
Missing= 1
23 (6)a
Female sex n (%) 103 (62.1)b,d 54 (69.2)b,d 51 (35.2)a,c,d 91 (56.5)b 132 (47.7)a,b
Married-in n (%) 0 (100.0) 8 (10.0) 36 (24.8)
Educational level
Primary school 118 (71.5)c 53 (68.0) 102 (70.3)c 88 (54.7)a,b
Secondary school 39 (23.6)c 18 (23.1)c 36 (24.8)c 58 (36.0)a,b
University degree 8 (4.9) 7 (9.0) 7 (4.8) 15 (9.3)
Missing= 1
Severe impairment during disorder 105 (65.6)c
Missing= 6
4 (5.6)a,c
Missing= 6
160 (99.4)a
History of psychosis 110 (66.3)c 4 (5.1)a,c 159 (98.8)a
History of suicide attempts 41 (24.7)b 2 (2.6)a,c 1 (0.7)a,c
Missing= 1
40 (24.8)b
Six unaffected individuals with a history of substance abuse were excluded from the analyses and are not shown in this table. Age and age at onset
were analysed using Mann–Whitney U-tests; median and median absolute deviation (MAD) are shown. Categorical values were analysed using
chi-squared (χ²) tests with two degrees (education) or one degree (other) of freedom; number (n) and percentage (%) of subjects are shown.
Missing: number of individuals with missing data. All subjects passed QC in the FAM sample (numbers as shown in the table), but 11 family
members were excluded during QC of the joint sample, therefore reported numbers differ slightly between comparisons. Note that the unaffected,
married-in family members were excluded from analyses of the combined data set (FAM+CC sample) unless specified otherwise. Differences
between the following groups were at least nominally significant (for details and p-values adjusted for multiple testing see Supplementary Table 1)
aDifferent from FAMBD
bDifferent from FAMunaffected
cDifferent from CCBD
dDifferent from CCcontrols
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Supplementary Table S2. For additional details, see the
Supplementary Methods.
For BD, MDD, and SCZ diagnoses, summary statistics
of GWAS by the Psychiatric Genomics Consortium
(PGC) were used as training data. For BD, the data freeze
contained 20,352 cases and 31,358 controls [12]. As
selected index patients from the ABiF families and the
unrelated Spanish BD case/control data set were part of
this BD GWAS, we recalculated summary statistics for
this PGC GWAS without these Spanish samples, to pre-
vent false-positive results caused by sample overlap
between training and test samples. For MDD and SCZ,
published data sets were used. These contained 130,664
cases and 330,470 controls for MDD [14] and 33,640
cases and 43,456 controls for SCZ [13]. There was no
overlap between the subjects included in those GWAS
and the ABiF and Spanish case/control samples. Variants
with an INFO metric of < 0.6 in the GWAS summary
statistics were removed.
Shared psychiatric PRS were generated using all variants
showing an association at p < 0.05 in the GWAS of BD, SCZ,
and MDD and for which effect sizes pointed in the same
direction across studies. For this shared set of variants, p-
values and effect sizes, used as weights in the PRS, were
obtained using random-effects meta-analysis. PRS were then
calculated using the meta-analysis summary statistics. We
generated disorder-specific summary statistics to assess
genetic risk unique to each disorder. To this end, genome-
wide inferred statistics (GWIS) were calculated as explained
in detail elsewhere [33]. For example, we calculated BD
GWAS summary statistics corrected for the MDD GWAS
results (BD-MDD). These BD-MDD GWIS results are similar
to results obtained from a conditional analysis for BD cor-
rected for MDD. They represent a genetic unique BD liability,
which is estimated based on the heritability of BD and the
coheritability of BD and MDD, both estimated using LD
score regression [34]. As recommended for this method,
variants with an INFO metric of <0.9 or >1.1 were removed.
Disorder-specific PRS, e.g., BD-MDD PRS, were then cal-
culated based on the corresponding GWIS summary statistics.
To confirm whether family members and BD cases
had an increased PRS specifically for the tested psychia-
tric disorders but not because of population or technical
differences between cohorts, PRS for late-onset Alzhei-
mer’s disease (LOAD) were calculated as a negative
control, based on a GWAS by the International Genomics
of Alzheimer’s Project (IGAP) with 17,008 cases
and 37,154 controls [35]. For additional details, see the
Supplementary Methods. Furthermore, 10,000 simulated
PRS for each of the ten p-value thresholds were calculated
as negative controls. To this end, random variants
from across the genome were drawn, using the same
number of variants as for the BD PRS at each threshold
and random effect sizes from the pool of all available BD,
SCZ, and MDD effects. The code for simulating PRS is
available at: https://gitlab.com/tillandlauer/abif-prs-ana
lyses/.
Statistical analysis
PRS analyses on binary variables (e.g., diagnoses and
comparisons between cohorts) were conducted in R with the
function glmm.wald of the package GMMAT, using a
logistic mixed model, fitted by maximum likelihood using
Nelder–Mead optimisation [36] to account for family
structure. For logistic models, PRS underwent Z-score
standardisation to generate comparable odds ratios (OR).
Family structure was modelled as a random effect, with a
genetic relationship matrix calculated on pruned genotype
data in GEMMA [37].
Linear mixed models (LMMs) taking family structure into
account were calculated using the function polygenic of the
package GenABEL [38] for analyses of quantitative variables
(anticipation and age at onset). In these analyses, test statis-
tics, including 95% confidence intervals (CI), were calculated
using bootstrapping (package boot [39, 40]) and p-values
were validated using permutation analysis (10,000 permuta-
tions). In these permutation analyses, the null distribution of
test statistics was empirically determined by repeating
regression analyses 10,000 times with random sampling of
phenotype data. To calculate a p-value, the number of tests
were counted where a model with a random genotype-
phenotype association showed the same or a more extreme p-
value than the correct, non-randomised model and this num-
ber was divided by the total number of tests (10,000).
For each analysis of PRS, all ten PRS p-value thresholds
were analysed. In analyses of the combined FAM and CC
data set, sex was used as a covariate. In the analysis of FAM
data alone, sex and age at the time of the interview were used
as fixed effects covariates; whether an individual had married
into the family was incorporated as a second random effect.
Following the hypothesis that family members or subjects
with a psychiatric diagnosis have increased PRS for psy-
chiatric disorders, one-sided p-values were calculated for all
PRS-based analyses. In all analyses, p-values below the sig-
nificance threshold α= 0.05 were considered as nominally
significant. Unless otherwise stated, this threshold was cor-
rected for 10 × 6= 60 tests using the Bonferroni method (α=
0.05/60= 8.33 × 10−4). For further details, see the Supple-
mentary Methods.
To determine whether population or technical differences
might have influenced the observed effects independently of
diagnosis groups, simulated PRS, generated as described
above, were analysed. For each model, association statistics
of the 10,000 simulated PRS were calculated for the ten p-
value thresholds; the disorder PRS at the threshold showing
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the lowest mean association p-value was analysed further:
The number of simulated PRS at this threshold that showed
the same or a stronger association was counted and com-
pared to the association of the disorder PRS. This count was
used as the number of successes in a binomial test to esti-
mate the probability of success. For computational effi-
ciency, models were fitted using restricted maximum
likelihood estimation and the average information optimi-
sation algorithm for this analysis.
Results
Figures 1 and 2 show the test statistics for the PRS with the
training GWAS p-value threshold pPRS that showed the
strongest association per PRS type. Full results for all ten
pPRS per PRS type calculated using logistic mixed models
are provided in Supplementary Figs. S1–S12 and in Sup-
plementary Tables S3–S11.
FAMBD cases had higher psychiatric PRS than
controls from the general population
On average, familial FAMBD cases had higher BD PRS than
unrelated CCcontrols across the pPRS thresholds (Fig. 1a, b;
Supplementary Figs. S1 and S2 and Supplementary Table
S3). The most substantial support for an increased BD PRS
was found with the threshold pPRS= 0.1 (OR= 2.97, one-
sided p= 1.9 × 10−11). FAMBD cases also had significantly
higher SCZ PRS than CCcontrols; the increase of the MDD
PRS was nominally significant (Fig. 1b).
Shared PRS generated from the variants associated jointly
with BD, SCZ, and MDD were significantly increased at
pPRS ≥ 0.01 in FAMBD cases compared to CCcontrols. The
GWIS BD-MDD PRS—the BD PRS corrected for associa-
tions shared with MDD—were significantly increased in
FAMBD cases compared to CCcontrols. All other disorder-
specific GWIS PRS were not significantly higher in FAMBD
cases after correction for multiple testing.
No significant increase was found for the negative-
control PRS for late-onset Alzheimer’s disease (LOAD) and
associations of the PRS for BD and SCZ and of the Shared
PRS were significantly stronger than simulated PRS in
FAMBD compared to CCcontrols (Table 2).
FAMBD cases had higher BD PRS than unrelated CCBD
cases
The BD PRS was significantly higher in FAMBD than in
CCBD cases at pPRS ≥ 0.05, but no other type of PRS was
increased in FAMBD compared to CCBD cases (Fig. 1c, d).
The association of the BD PRS was significantly stronger
than simulated PRS (Table 2).
Unaffected family members showed higher
psychiatric PRS than CC controls
In the comparison of FAMunaffected to CCcontrols, PRS for BD
and SCZ were significantly higher in unaffected family
members (Fig. 1e, f). The increases of the MDD, Shared, BD-
MDD, and SCZ-BD GWIS PRS were nominally significant.
The associations of BD and SCZ PRS were significantly
stronger than the associations of simulated PRS (Table 2).
FAMBD cases had an increased PRS specifically for
BD
In comparison to FAMunaffected, the BD PRS and the BD-
MDD disorder-specific PRS were significantly higher in
FAMBD (Fig. 2a, b). The Shared and the BD-SCZ PRS were
increased at nominal significance.
Effects of assortative mating on BD PRS in family
members
Eight of the 44 individuals who had married into the
families had a diagnosis of MDD and none of BD (Table 1).
While the unaffected married-in individuals had higher BD
PRS than CCcontrols (p= 6.5 × 10−5), their BD PRS was not
higher than the PRS of other FAMunaffected (Fig. 2c; Sup-
plementary Fig. S6 and Supplementary Table S7). We also
examined possible anticipation of BD in the families: nei-
ther did the BD PRS increase significantly over generations
nor did the age at onset decrease over time (Fig. 2d; Sup-
plementary Fig. S7 and Supplementary Table S8).
FAMMDD cases had higher psychiatric PRS than
CCcontrols
In comparison to CCcontrols, FAMMDD cases had sig-
nificantly higher BD and MDD PRS, increases of the
Shared and SCZ PRS were nominally significant (Supple-
mentary Figs. S8 and S9 and Supplementary Table S9).
Both the BD and MDD PRS were increased at nominal
significance when comparing FAMMDD to FAMunaffected
(Supplementary Fig. S10 and Supplementary Table S10).
Notably, in both comparisons, FAMMDD showed a nominal
increase in SCZ-MDD PRS, but not in SCZ-BD PRS.
Discussion
Genome-wide association studies in large samples of
unrelated patients and controls have unravelled the poly-
genic nature of BD, i.e., many common variants, each with
a small effect size, contribute to BD. It has also been con-
sistently shown that BD, MDD, and SCZ share many
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risk-conferring variants. The aim of the present study was to
investigate whether common variants also contribute to BD
in families with a high density of the disorder and if so,
whether these variants are specific to BD.
We found that, compared to CCcontrols, unrelated subjects
from the general population unscreened for BD, affected and
unaffected ABiF family members had an elevated genetic
risk for the tested psychiatric disorders, mainly for BD but
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also for SCZ. FAMBD cases were characterised by a parti-
cularly high load of BD-specific risk variants: The strongest
association observed across all comparisons was the increase
of the BD PRS in FAMBD compared to CCcontrols. In addi-
tion, the BD but not the SCZ and MDD PRS of FAMBD
were significantly higher than the PRS of unrelated CCBD
cases and unaffected family members. Together with the
disorder-specific GWIS PRS, these results support the major
contribution of BD-associated variants to the high density of
the disorder in the investigated families.
An increased polygenic psychiatric risk has also been
described in other studies of BD multiplex families [41–
43]. However, the scope and results of these studies dif-
fered from the present study to some extent: Fullerton
et al. [41] described an increased BD PRS in affected
family members compared to unrelated controls and,
when selecting families with a high polygenic BD risk
load, also to unaffected family members. They con-
structed PRS only based on a small set of 32 SNPs from
an older GWAS [10], and no other PRS were investigated.
De Jong et al. [43] focused their analyses in a large
Brazilian family with BD and MDD on assortative mating
and anticipation and found BD and SCZ PRS to be
increased at nominal significance in affected compared to
unaffected members. In a large Swedish pedigree with
mainly BD but also some SCZ cases, Szatkiewicz et al.
[42] reported increased SCZ PRS in affected family
members compared to family-level and population con-
trols, as well as BD PRS increased at nominal significance
in affected family members compared to family controls.
However, no differences were observed between unaf-
fected family members and population controls. Of note,
none of these studies investigated differences in PRS
between families and unrelated BD cases.
Compared to the CCBD in our study, FAMBD displayed,
apart from an earlier age at onset, signs of a less severe
clinical picture, i.e., less frequent impairment and less
psychosis. This could be explained by the fact that CCBD
cases were almost all BD-I patients recruited from con-
secutive admissions to a hospital, while most of the FAMBD
cases were reached through other family members in the
context of the study. Apart from this, the FAMBD did not
display any striking differences in clinical features com-
pared to the CCBD. Thus, we consider it likely that the
increased PRS in the FAMBD is linked to the familial
aggregation and not to clinical characteristics.
It appears striking that none of the ABiF family members
have been diagnosed with SCZ. However, this can most
likely be attributed to ascertainment bias as the recruitment
strategy focused on BD multiplex families. With respect to
this lack of SCZ diagnoses in the ABiF families, it is of
interest that the family members showed not only an
increased BD PRS but also increased SCZ and Shared PRS
compared to unrelated controls. This increase could be an
indirect consequence of the genetic correlation between BD
and SCZ [14, 16, 18–21]. Furthermore, affected family
members also had higher Shared PRS than CCcontrols. Of the
psychiatric disorder GWAS data sets (i.e., SCZ, BD, and
MDD) used in the present analysis, the SCZ GWAS both
identified the largest amount of risk loci (108, 30, and 44,
respectively) and the corresponding PRS explained the
highest amount of case/control variance (7%, 4%, and 2% on
a liability scale, respectively) [12–14]. Taking this and the
genetic correlations between the disorders into account, the
SCZ PRS might have included more cross-disorder signals
with smaller effects than the PRS of BD and MDD. If family
members had an increased Shared risk burden, this cross-
disorder risk might have rendered them vulnerable to psy-
chiatric disorders in general, with the high BD PRS then
shaping the final BD diagnosis outcome. Of note, the analyses
of FAMMDD cases are discussed in the Supplementary Data.
Our study furthermore indicates that assortative mating
may have contributed to the increased BD PRS in the
ABiF families: in their study, de Jong et al. [43] found no
increased PRS in married-in subjects, but an increase of
polygenic risk and a decrease in age at onset over gen-
erations. We observed that individuals who married into
the ABiF families had higher BD PRS than CCcontrols, and
Fig. 1 Comparison of PRS between FAM and CC samples. Married-in
family members were excluded from these analyses. The plots show
one-sided p-values, following the hypothesis that family members
have higher PRS than individuals from the CC samples. All PRS have
been normalised using Z-score standardisation. a, b Comparison of
FAMBD cases to CCcontrols. a FAMBD cases had higher BD PRS across
all ten pPRS thresholds. The plot shows odds ratios (OR, y-axis, filled
circles) and 95% confidence intervals (CI); pPRS thresholds are shown
on the x-axis. Results for each threshold are coloured by their degree of
significance (one-sided p-values): red= not significant, orange=
nominally significant, green= significant after Bonferroni correction
for multiple testing (α= 0.05/60= 0.00083). The top-associated PRS
(pPRS= 0.1) is indicated in bold font and was marked by a magenta
circle (also in b). b For ten different PRS, this plot shows association
statistics for the top-associated pPRS thresholds. The x-axis shows ORs.
BD, SCZ, MDD: Standard PRS using the respective PGC GWAS
summary statistics. Shared: Shared psychiatric PRS (SNPs with BD,
MDD, SCZ p < 0.05, random-effects meta-analysis). BD-SCZ, BD-
MDD: BD-specific GWIS PRS corrected for SCZ and MDD,
respectively. SCZ-BD and MDD-BD: GWIS PRS for SCZ and MDD,
each corrected for BD. LOAD: PRS for late-onset Alzheimer’s dis-
ease. Simulated: Mean and CI of the 10,000 simulated PRS at the pPRS
with the lowest mean association p-value of all simulated PRS. The
column to the left of the plot: pPRS with the strongest association.
Supplementary Fig. S2 shows plots for all pPRS. Column to the right:
pone-sided= one-sided p-value. For full association test statistics, see
Supplementary Table S3. Bonferroni= significant after Bonferroni
correction for multiple testing; nominal= nominally significant (p <
0.05); n.s.= not significant. c, d Comparison of FAMBD cases and
unrelated CCBD cases. See Supplementary Fig. S3 and Table S4 for
more detailed plots and full association test statistics. e, f Comparison
of FAMunaffected and CCcontrols. See Supplementary Fig. S4 and Table
S5 for more detailed plots and full association test statistics
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their BD risk load was similar to other FAMunaffected. At
the time of the interview, none of the married-in family
members had a diagnosis of BD. Nevertheless, their
increased BD PRS suggests that assortative mating may
have occurred. Unaffected individuals with an above
average BD PRS may display sub-threshold character-
istics of BD, such as a broader range of emotions [44–46].
Consistent with the observation that married-in subjects
did not have higher BD PRS than the other FAMunaffected,
no increase in BD PRS was found across generations.
However, assortative mating may have contributed to the
establishment and maintenance of a high genetic risk load
for BD in these families. Furthermore, assortative mating
may have already occurred in previous generations, for
which no DNA was available. Of note, DNA was not
available for all ABiF family members of the current
FAMBD cases vs. FAMunaffected
A
5×
10
-
8
1×
10
-
7
1×
10
-
6
1×
10
-
5
1×
10
-
4
1×
10
-
3
1×
10
-
2
5×
10
-
2
1×
10
-
1
2×
10
-
1
BD PRS p-value threshold
0.89
1.00
1.12
1.25
1.38
1.50
1.62
1.75
1.88
2.00
O
dd
s 
Ra
tio
 a
nd
 9
5 
%
 C
I
0.394
0.395
0.396
0.397
0.398
0.399
0.400
0.401
CC
controls
FAM
married−in
FAM
unaffected
CC
BD
FAM
BD
*
n.s.
277 35 107 161 163n
B
D
 P
R
S 
(p
 
=
 5
×1
0-
2 )
Assortative MatingC
Unaffected BD
0.44
0.45
0.46
0.47
0.48
0.49
0.50
0.51
2 3 41
0.41
0.42
0.43
0.40
B
D
 P
R
S 
(p
 
=
 1
×1
0-
5 )
2 3 41 2 3 41
Anticipation
Unaffected BD MDD
Generation
31 69 9n 51 100 14 1 20 42 80 0
D
B
Shared
SCZ
MDD
BD (see A)
BD-SCZ
BD-MDD
pPRS pone-sided
1.3×10-04
8.9×10-02
1.5×10-01
1×10-4
1×10-4
1×10-1
3.9×10-03
3.8×10-021×10-2
1×10-3
4.9×10-04
5.8×10-01
1×10-5
1×10-3
1 1.750.89 2.0
Odds Ratio and 95 % CI
Bonferroni Nominal n.s.Significance:
1.51.25
LOAD
PRS
0.8
SCZ-BD
MDD-BD
3.2×10-015×10-8
2.3×10-011×10-2
Fig. 2 a, b Comparison of PRS between FAMBD cases and FAMu-
naffected. The plots show one-sided p-values, following the hypothesis
that BD cases have higher PRS than unaffected individuals. Further
details of the plots are as described in the legend for Fig. 1. See
Supplementary Fig. S5 and Table S6 for more detailed plots and full
association test statistics. c, d Analyses of assortative mating (c) and
anticipation (d). These plots were not adjusted for covariates; n=
sample size. The y-axis shows the PRS values. c: Assortative mating.
The plot shows violin- and boxplots of the BD PRS (pPRS= 0.05),
comparing unaffected, married-in individuals with no parent among
the ABiF families to other FAM and CC subjects. At pPRS= 0.05,
married-in family members showed the highest BD PRS compared to
CCcontrols (p= 6.5 × 10−5, Supplementary Fig. S6A and Table S7). The
BD PRS of married-in individuals was not significantly higher than the
PRS of FAMunaffected at any pPRS (p ≥ 0.167, Supplementary Fig. S6B
and Table S7). Covariate used: sex. One-sided p-values were calcu-
lated, following the hypothesis that married-in individuals have higher
PRS than other unaffected subjects. Note that, in the context of
assortative mating, the boxplots of affected BD cases are displayed for
reference only and have not been included in the analysis. d Antici-
pation: the BD PRS did not increase across generations. The plot
shows violin- and boxplots of the BD PRS (pPRS= 1 × 10−5) across
different generations of the FAM sample for the three diagnosis
groups. At pPRS= 1 × 10−5, the association of the BD PRS with gen-
eration was strongest but not significant (p= 0.45; Supplementary
Fig. S7A and Table S8). Married-in family members were excluded
from this analysis. Covariates used: sex, age at the interview, diag-
nostic group. One-sided p-values were calculated, following the
hypothesis that the PRS increase across generations
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generations, limiting the scope of the analysis of assor-
tative mating.
Although both the FAM and CC samples were recruited
in Spain [9], minor population differences may have influ-
enced the present results. Even if such minor differences
existed, it is unlikely that they caused the highly significant
associations observed for the psychiatric PRS, given that the
pairwise genetic relationship matrix was used as a random
effect in the association analyses. Additionally, results from
three further analyses support our assumption that sys-
tematic differences between the genotype data of FAM,
CCcontrols, and CCBD samples did not distort our findings:
First, we did not find significant differences between the
cohorts in a population substructure analysis (see Supple-
mentary Fig. S11 and Supplementary Methods). Second,
PRS for LOAD were not significantly increased in family
members in any analysis. Since LOAD shows no genetic
correlation with BD, MDD, or SCZ [14, 47, 48], this result
further supports the specificity of our analyses. Third, when
a psychiatric disorder PRS was significantly increased in
family members, this association was stronger than for
simulated PRS. While these findings cannot entirely
exclude the influence of unknown confounders on our
results, we consider them as strong evidence that the
high psychiatric PRS observed in family members
compared to controls cannot be attributed to population or
technical differences between the cohorts.
The lower a pPRS threshold in the GWAS training data,
the fewer SNPs were included in the calculation of the
corresponding PRS. In most cases, significant differences
between groups were not observed for these low pPRS but
the higher thresholds based on thousands of variants. This is
commonly observed and in line with the polygenic nature of
psychiatric disorders as complex disorders, with genome-
wide significant SNPs only accounting for a small share of
the polygenic signal. The training GWAS used for BD,
SCZ, and MDD, the largest available for these phenotypes,
differ in the number of included subjects, their statistical
power, and the number of identified signals. Therefore, the
derived PRS also differ in the number of SNPs used in the
calculation of each threshold (see Supplementary Table S2).
However, even though the BD GWAS was based on the
smallest number of subjects and contained the lowest
number of genome-wide-associated loci among the three
GWAS, the BD PRS showed the strongest associations with
BD case status or family membership, underlining the
substantial contribution of BD risk variants to the devel-
opment of BD in the ABiF families.
One limitation of the study is that the subjects of the
unrelated control cohort were not systematically screened
Table 2 The psychiatric disorder
PRS can distinguish better
between groups than
simulated PRS
Group Disorder PRS Simulated PRS
min. pPRS
N simulated PRS
with p ≤ p of
disorder PRS
Prob. of
success
95% CI
FAMBD vs. CCcontrols BD 1 × 10
−5 0 <1× 10−4 0–0
SCZ 1 × 10−5 0 <1× 10−4 0–0
MDD 1 × 10−5 91 0.0091 0.007–0.011
Shared 1 × 10−5 2 0.0002 0–0.001
FAMBD vs. CCBD BD 1 × 10
−7 0 <1× 10−4 0–0
SCZ 1 × 10−7 2858 0.2858 0.277–0.295
MDD 1 × 10−7 744 0.0744 0.069–0.080
Shared 1 × 10−7 2229 0.2229 0.215–0.231
FAMunaffected vs. CCcontrols BD 1 × 10
−7 0 <1× 10−4 0–0
SCZ 1 × 10−7 0 <1× 10−4 0–0
MDD 1 × 10−7 37 0.0037 0.003–0.005
Shared 1 × 10−7 74 0.0074 0.006–0.009
FAMMDD vs. CCcontrols BD 2 × 10
−1 0 <1× 10−4 0–0
SCZ 2 × 10−1 409 0.0409 0.037–0.045
MDD 2 × 10−1 2 0.0002 0–0.001
Shared 2 × 10−1 125 0.0125 0.010–0.015
In binomial tests with 10,000 trials, the number of successes was the number of simulated PRS that showed
the same or a stronger association than the disorder PRS (one-sided p-values). The 10,000 simulated PRS
with ten p-value thresholds each were calculated by drawing random variants from across the genome, using
the same number of variants as for the BD PRS at each threshold and random effect sizes from the pool of all
available BD, SCZ, and MDD effects. For the present test, the pPRS of the simulated PRS showing the lowest
mean association p-value was chosen. Prob.= binomial test probability estimate of success; CI= confidence
interval of the probability estimate, both calculated using the R package binom (method: exact). Significance
threshold: 0.05/16= 0.003125, comparisons surpassing this threshold are shown in bold font
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for psychiatric disorders. The lifetime prevalence of uni-
polar depression in this cohort (up to 14.4% until the time of
the interview) was in line with typically observed numbers
[27], the prevalence of BD was not assessed. However, as
BD has a lifetime prevalence of ~1%, we expect up to three
BD cases among the 277 controls, a number we consider
unlikely to have markedly influenced our results. Moreover,
using controls unscreened for BD instead of “super-healthy”
controls as a comparison to family members and unrelated
BD cases represents a conservative approach and
thereby strengthens the observed group differences in
psychiatric PRS.
Similarly, around one third of the CCBD reported a family
history of BD. The CCBD thus do not represent a sample of
truly sporadic BD cases. However, the aim of our study was
to investigate how members of multiplex BD families differ
from typical BD cases regarding the polygenic contribution to
their disorder. The observation that ABiF multiplex cases
showed a higher polygenic psychiatric risk than CCBD,
despite part of the CC cases also reporting a family history for
BD, thus rather strengthens the validity of our findings.
The present study generated substantial evidence that
members of the ABiF families, including unaffected sub-
jects, carried a higher risk burden of common genetic risk
variants than an unrelated control sample mainly for the
psychiatric disorders BD and SCZ and, at least the
FAMMDD cases, for MDD. In line with previous theoretical
assumptions [49] and preliminary results from a pilot study
in a single ABiF family [26], our results suggest that a high
polygenic load of common risk variants is a major con-
tributor to the increased risk for BD and MDD in families
with a high density of BD. However, given the modest
effect sizes of the PRS, they explained only a fraction of the
phenotypic variance, and rare mutations such as copy
number variants [50] or rare single-nucleotide variants
likely also play an important role in each of the families.
Sequencing studies carried out in multiplex families have
suggested rare variants are involved in the aetiology of BD
[51–53]. To date, however, it has proven difficult to identify
replicable causal associations between rare variants and BD
susceptibility. In a pilot study that analysed a single ABiF
pedigree, we did not identify any rare causal variants for BD
[26]. The analysis of rare variants in the remaining ABiF
families using next-generation sequencing technologies is
envisioned for the future, including integrative analyses in
international consortia such as the Bipolar Sequencing
Consortium [54]. Of note, the present analyses did not
assess single families separately, but integrated PRS asso-
ciations across all examined 33 ABiF families. Thus, the
degree to which common and rare variants shaped the
emergence of psychiatric disorders may vary between
families.
Furthermore, PRS are commonly based on and applied to
sets of unrelated individuals, and polygenic risk might act
differently in the case of familial genetic background.
Moreover, a broad range of environmental factors have
been shown to influence the risk of psychiatric disorders
and might act on top of the increased genetic risk in these
families. However, environmental factors have not been
systematically assessed in the present study. To further
enhance our understanding regarding the aetiology of BD,
integrated analyses of common and rare variants, as well as
of environmental risk in the ABiF families are warranted in
the future.
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